Drug combination useful for prevention of restenosis
View Patent ↗The current invention comprises an approach to solving the clinical problem of restenosis, which involves the administration of combinations of drugs to patients undergoing PTCA or stent implantation. In one embodiment of the invention, an antiproliferative agent such as rapamycin, vincristine or taxol is administered in combination with the antiinflammatory agent, dexamethasone, to patients systemically, either subcutaneously or intravenously. In another embodiment of the invention, the antiproliferative and antiinflammatory agents are bound in a single formulation to the surface of a stent by means of incorporation within either a biodegradable or biostable polymeric coating. Alternatively, such drug combinations could be incorporated into a stent constructed with a grooved reservoir.
1. A method for treating restenosis comprising an intravascular infusion or delivery by release from a surface of a stent of a combination of at least two agents, including an anti-proliferative agent for inhibiting smooth muscle cell growth comprising rapamycin or an analogue thereof and an anti-inflammatory agent for inhibiting smooth muscle growth, both said agents contained in therapeutic dosage amounts.
2. The method of claim 1 wherein the combination of at least two agents further includes a tyrosine kinase inhibitor.
3. The method of claim 1 wherein the anti-inflammatory agent comprises dexamethasone.
4. The method of claim 1 wherein the combination of at least two agents further includes a growth factor or cytokine signal transduction inhibitor.
5. The method of claim 1 wherein the combination of at least two agents further includes an inhibitor of extracellular matrix synthesis.
6. The method of claim 5 wherein the inhibitor of extracellular matrix synthesis comprises halofuginone and the anti-proliferative agent is taken from a group consisting of rapamycin, taxol, or vincristine.